201 related articles for article (PubMed ID: 12633823)
1. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy.
Silversides CK; Webb GD; Harris VA; Biggar DW
Am J Cardiol; 2003 Mar; 91(6):769-72. PubMed ID: 12633823
[No Abstract] [Full Text] [Related]
2. Effect of deflazacort on cardiac and sternocleidomastoid muscles in Duchenne muscular dystrophy: a magnetic resonance imaging study.
Mavrogeni S; Papavasiliou A; Douskou M; Kolovou G; Papadopoulou E; Cokkinos DV
Eur J Paediatr Neurol; 2009 Jan; 13(1):34-40. PubMed ID: 18406648
[TBL] [Abstract][Full Text] [Related]
3. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
Alman BA; Raza SN; Biggar WD
J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
[TBL] [Abstract][Full Text] [Related]
4. Deflazacort treatment of Duchenne muscular dystrophy.
Biggar WD; Gingras M; Fehlings DL; Harris VA; Steele CA
J Pediatr; 2001 Jan; 138(1):45-50. PubMed ID: 11148511
[TBL] [Abstract][Full Text] [Related]
5. Identifying evidence of cardio-renal syndrome in patients with Duchenne muscular dystrophy using cystatin C.
Villa CR; Kaddourah A; Mathew J; Ryan TD; Wong BL; Goldstein SL; Jefferies JL
Neuromuscul Disord; 2016 Oct; 26(10):637-642. PubMed ID: 27542440
[TBL] [Abstract][Full Text] [Related]
6. Cardiac profile of asymptomatic children with Becker and Duchenne muscular dystrophy under treatment with steroids and with/without perindopril.
Mavrogeni S; Giannakopoulou A; Papavasiliou A; Markousis-Mavrogenis G; Pons R; Karanasios E; Noutsias M; Kolovou G; Papadopoulos G
BMC Cardiovasc Disord; 2017 Jul; 17(1):197. PubMed ID: 28738778
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
Balaban B; Matthews DJ; Clayton GH; Carry T
Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center.
Marden JR; Freimark J; Yao Z; Signorovitch J; Tian C; Wong BL
J Comp Eff Res; 2020 Feb; 9(3):177-189. PubMed ID: 31922454
[No Abstract] [Full Text] [Related]
9. Deflazacort increases laminin expression and myogenic repair, and induces early persistent functional gain in mdx mouse muscular dystrophy.
Anderson JE; Weber M; Vargas C
Cell Transplant; 2000; 9(4):551-64. PubMed ID: 11038071
[TBL] [Abstract][Full Text] [Related]
10. Steroid therapy and cardiac function in Duchenne muscular dystrophy.
Markham LW; Spicer RL; Khoury PR; Wong BL; Mathews KD; Cripe LH
Pediatr Cardiol; 2005; 26(6):768-71. PubMed ID: 15990951
[TBL] [Abstract][Full Text] [Related]
11. Precordial R wave height does not correlate with echocardiographic findings in boys with Duchenne muscular dystrophy.
Thrush PT; Edward N; Flanigan KM; Mendell JR; Allen HD
Congenit Heart Dis; 2013; 8(6):561-7. PubMed ID: 23510265
[TBL] [Abstract][Full Text] [Related]
12. Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy.
Tandon A; Villa CR; Hor KN; Jefferies JL; Gao Z; Towbin JA; Wong BL; Mazur W; Fleck RJ; Sticka JJ; Benson DW; Taylor MD
J Am Heart Assoc; 2015 Mar; 4(4):. PubMed ID: 25814625
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
Wong BL; Christopher C
J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
[TBL] [Abstract][Full Text] [Related]
14. Left ventricular dysfunction in Duchenne muscular dystrophy.
James KA; Gralla J; Ridall LA; Do TN; Czaja AS; Mourani PM; Ciafaloni E; Cunniff C; Donnelly J; Oleszek J; Pandya S; Price E; Yang ML; Auerbach SR
Cardiol Young; 2020 Feb; 30(2):171-176. PubMed ID: 31964455
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.
Ogata H; Ishikawa Y; Ishikawa Y; Minami R
J Cardiol; 2009 Feb; 53(1):72-8. PubMed ID: 19167641
[TBL] [Abstract][Full Text] [Related]
16. Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment.
Kim HK; Laor T; Horn PS; Wong B
Korean J Radiol; 2010; 11(3):304-11. PubMed ID: 20461184
[TBL] [Abstract][Full Text] [Related]
17. Progressive left ventricular dysfunction and myocardial fibrosis in Duchenne and Becker muscular dystrophy: a longitudinal cardiovascular magnetic resonance study.
Aikawa T; Takeda A; Oyama-Manabe N; Naya M; Yamazawa H; Koyanagawa K; Ito YM; Anzai T
Pediatr Cardiol; 2019 Feb; 40(2):384-392. PubMed ID: 30564867
[TBL] [Abstract][Full Text] [Related]
18. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.
Markham LW; Kinnett K; Wong BL; Woodrow Benson D; Cripe LH
Neuromuscul Disord; 2008 May; 18(5):365-70. PubMed ID: 18436445
[TBL] [Abstract][Full Text] [Related]
19. Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy.
Jensen L; Petersson SJ; Illum NO; Laugaard-Jacobsen HC; Thelle T; Jørgensen LH; Schrøder HD
J Musculoskelet Neuronal Interact; 2017 Jun; 17(2):8-18. PubMed ID: 28574407
[TBL] [Abstract][Full Text] [Related]
20. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
McAdam LC; Mayo AL; Alman BA; Biggar WD
Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
